-
Sector Analysis
Coronary Stents Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Coronary Stents Market Overview The coronary stents market size was valued at $4.37 billion in 2023. The market will grow at a CAGR of less than 1% during 2023-2033. Factors such as rapidly changing lifestyles and growing unhealthy diets are leading to increased risk of coronary heart disease, which will drive the market growth in coming years. A coronary stent is an expandable perforated tube that is inserted into a natural conduit of the body to prevent or counteract a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Non-Small Cell Lung Cancer Drug Details: Pucotenlimab (Puyouheng)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Metastatic Colorectal Cancer Drug Details: Pucotenlimab (Puyouheng) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Hepatocellular Carcinoma Drug Details: Pucotenlimab (Puyouheng) is a humanized...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Pucotenlimab...
-
Sector Analysis
Prosthetic Heart Valves Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Prosthetic Heart Valves Market Report Overview The prosthetic heart valves market size was valued at $2.15 billion in 2023. The prosthetic heart valves market will grow at a CAGR of more than 3% from 2023 to 2033. The growing aging population across the globe and the associated valvular degeneration is primarily driving the prosthetic heart valve market growth. Prosthetic Heart Valves Market Outlook 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Prosthetic Heart Valves Market Forecast,...
-
Product Insights
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Drugs In Development, 2023’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...